Can capmatinib effectively treat the disease?

Introduction: Capmatinib is a highly selective small molecule MET inhibitor. In May 2020, the US FDA approved Capmatinib for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping (METEX14) mutations. Capmatinib is the first FDA-approved targeted therapy for MET patients.

Generic version of Capmatinib

The more common generic versions include Laos Lucius Pharmaceuticals version, Bangladesh Everest version, Laos Daxiong Pharmaceutical version, Laos Second Pharmaceutical Factory version, etc. There are many manufacturers of generic capmatinib drugs, and they are basically the same as the original drug in terms of drug ingredients, mechanism, efficacy, etc., but the price will be cheaper than the original drug.

Can the generic version of capmatinib also be effective in treating diseases?

There is not much difference in quality and effect between generic capmatinib drugs and the original drug. Generic drugs do not have the huge investment in early research and development of the original drug, so the cost and price are lower. However, the efficacy of generic drugs is basically the same as that of the original drug. Therefore, generic drugs are also an effective treatment option. Generic drugs must go through the corresponding approval process before they can be marketed, and their safety and effectiveness should be theoretically equivalent to that of the original drugs. Patients should be guided by their doctors when choosing generic drugs to ensure the safety and effectiveness of the drugs.

Precautions when using capmatinib

Capmatinib can cause interstitial lung disease, pneumonia, hepatotoxicity, photosensitivity and embryo-fetal toxicity. Based on clear positive signals for phototoxicity in early cell laboratory studies, people may be more sensitive to sunlight and should be advised to take precautions while taking capmatinib by covering their skin and using sunscreen to avoid tanning. Capmatinib may cause harm to the developing fetus or newborn and is therefore contraindicated in pregnant women.

Usage and dosage of Capmatinib

The recommended dose of Capmatinib is 400mg orally taken twice a day (2 tablets*200mg) each time. It can be taken with or without food. Swallow the Capmatinib tablet as a whole. Do not break, crush or chew the tablet. If the patient misses a dose or vomits, do not take the missed dose but take it at the next scheduled time.